Eris Lifesciences Q1 FY27 PAT Rises 14.5% to ₹143 Crore; Revenue Up 13%

BY ADMIN • FILED 29 Jul 2026, 6:22 PM

Eris Lifesciences Limited has reported a strong financial performance for the quarter ended June 30, 2026 (Q1 FY27), driven by healthy growth in its domestic branded formulations business, expanding insulin franchise, and continued leadership in the GLP-1 therapy segment.

The company posted double-digit growth in revenue and profitability while strengthening its position in India’s chronic therapy market through product expansion and market share gains.

Q1 FY27 Financial Highlights

Eris Lifesciences delivered solid growth across its key financial metrics during the first quarter of FY27.

Revenue from Operations: Increased 13% year-on-year (YoY) to ₹873 crore, compared with ₹773 crore in Q1 FY26.
Profit After Tax (PAT): Rose 14.5% YoY to ₹143 crore, up from ₹125 crore in the corresponding quarter last year.
EBITDA: Grew 7% YoY to ₹296 crore, compared with ₹277 crore in Q1 FY26.
EBITDA Margin: Maintained a healthy 34%, reflecting continued operational efficiency.

Domestic Branded Formulations Drive Growth

The company’s Domestic Branded Formulations (DBF) business remained the primary growth engine during the quarter.

Key highlights include:

Revenue: ₹801 crore, up 14.2% YoY from ₹702 crore.
EBITDA: ₹278 crore.
EBITDA Margin: 35%.
Organic Growth: 14.2%, with seven of the company’s ten major therapy segments delivering double-digit growth.

The strong performance underscores Eris’ continued focus on chronic and specialty therapies, which remain key contributors to long-term growth.

Insulin Business Continues to Expand

The company’s insulin portfolio recorded robust growth following the integration of the Biocon insulin business.

Highlights include:

Insulin Portfolio Revenue: ₹412 crore, representing 26.4% YoY growth.
Market Share: Increased to 16% in the Human Insulin + Glargine segment, up from 9% immediately after the Biocon acquisition.

Eris also announced plans to enter the rapidly growing ₹2,309 crore Insulin Analogs market, with a pipeline of five new products expected to be launched beginning in FY28.

Leadership in the GLP-1 Segment

The company continued to strengthen its position in the fast-growing GLP-1 diabetes therapy market.

Its generic semaglutide brand Suvenda emerged as:

No. 1 in prescription market share (approximately 21%).
No. 1 in unit sales (approximately 20%).

During its first full quarter in the market, the brand generated ₹12 crore in revenue within an estimated ₹88 crore generic semaglutide market, reflecting strong physician acceptance and market penetration.

International Business

Eris’ international business, operated through Swiss Parenterals, continued to deliver steady performance.

International Revenue: ₹72 crore, up 5% YoY.
International EBITDA: ₹18 crore.

The company also stated that Corrective and Preventive Actions (CAPA) are progressing across its European manufacturing facilities, with the objective of achieving regulatory audit readiness by December 2026.

Business Outlook

With approximately 85% of its portfolio focused on chronic and sub-chronic therapies, Eris Lifesciences remains well-positioned to benefit from India’s long-term healthcare growth trends.

Management expects business momentum to strengthen further as:

The Oral Anti-Diabetes (OAD) franchise continues to expand.
The Cardiac portfolio regains full growth momentum.
New biosimilar products are introduced.
The company enters the insulin analog market beginning in FY28.